Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD133+ bone marrow cells
- Development stage
- Phase 2
- Lead developer
- Deutsches Herzzentrum Berlin
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramyocardial
01
Overview
Autologous CD133+ bone marrow cells are an investigational cell therapy product consisting of a purified population of hematopoietic stem and progenitor cells (HSPCs) harvested from a patient's own bone marrow. These cells are enriched for the CD133 (Prominin-1) surface marker, a glycoprotein associated with primitive stem cells that possess high angiogenic and vasculogenic potential. The treatment involves harvesting bone marrow, typically via aspiration, followed by magnetic bead-based selection of CD133+ cells. These cells are then delivered via direct intramyocardial injection into the border zone of infarcted or ischemic myocardium, often during coronary artery bypass graft (CABG) surgery. The therapeutic mechanism relies on the cells' ability to home to ischemic regions and release paracrine factors (such as VEGF) that promote neovascularization, limit cardiomyocyte apoptosis, and potentially support myocardial regeneration, thereby aiming to improve left ventricular ejection fraction (LVEF) and cardiac perfusion in patients with chronic ischemic heart disease and heart failure.
- Other names
- autologous CD133+ enriched bone marrow cellsCD133+ bone marrow stem cellsCD133+ bone marrow progenitor cellsCD133-enriched bone marrow cellsCD-133-enriched bone marrow cellsCD 133-enriched bone marrow cellsautologous CD133 positive bone marrow cells
Beyond the preview
Go deeper on autologous CD133+ bone marrow cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD133+ bone marrow cells.